Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT00320775
- Locations
- 🇺🇸
Retina Centers, PC, Tuscon, Arizona, United States
🇺🇸Loma Linda University Health Care, Loma Linda, California, United States
🇺🇸Johns Hopkins Hospital School of Medicine, Baltimore, Maryland, United States
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
- Conditions
- Interventions
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT00288704
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT00082823
- Locations
- 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT00083213
- Locations
- 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT00045266
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT00036946
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States